

## **Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation**

**Lund, Sweden, 17 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX)**, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today presents preclinical data on the immune activating antibody ATOR-1015 at the American Association of Cancer Research (AACR) Annual Meeting 2018 taking place in Chicago, Illinois. ATOR-1015 is a first-in-class bispecific tumor-directed antibody, targeting CTLA-4 and OX40, designed to selectively activate the immune system in the tumor, without increasing systemic toxicity.

The preclinical data demonstrate that ATOR-1015 physically localizes to the tumor and selectively activates the immune system in the tumor area, confirming the intended ATOR-1015 mechanism of action.

ATOR-1015 is primarily designed for combination therapy with a PD-1 blocking antibody, and the potential of this approach is supported with preclinical data reporting enhanced anti-tumor effect of ATOR-1015 in combination with an anti-PD-1 antibody, as compared to anti-PD-1 monotherapy. In addition, ATOR-1015 demonstrated superior efficacy compared to mono-targeting CTLA-4 and OX40 antibodies.

“The results presented in Chicago confirm that our CTLA-4 bispecific antibody ATOR-1015 selectively activates the immune system in the tumor area. This offers great potential for an improved benefit/risk profile for cancer patients. We are more and more excited about the significant prospects for this unique compound, particularly in combination with PD-1 blockers, and are looking forward to initiate clinical development later in the year”, said Per Norlén CEO of Alligator Bioscience.

Alligator is planning to initiate an ATOR-1015 Phase I study during the second half of 2018.

A poster with the title ***“CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation”*** is showcased today at 8-12 a.m. EDT and is also available on the company web page [www.alligatorbioscience.com](http://www.alligatorbioscience.com).

**For further information, please contact:**

Cecilia Hofvander, Director Investor Relations & Communications

Phone +46 46 286 44 95

E-mail: [cecilia.hofvander@alligatorbioscience.com](mailto:cecilia.hofvander@alligatorbioscience.com)

*The information was submitted for publication, through the agency of the contact person set out above, at 3 p.m. CEST on 17 April 2018.*

### **About Alligator Bioscience**

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527).

ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit [www.alligatorbioscience.com](http://www.alligatorbioscience.com).